[Ip-health] MSF at TB Conf 3 Nov -- XDR-TB: can the R&D pipelines respond to the challenge?

[Sheila.SHETTLE@geneva.msf.org]

MSF seminar at the Palais des Congr=C3=A8s, Paris=0D
ROOM 343=0D
Friday 3rd November, 4.30 =E2=80=93 6.30pm=0D
Dr Tido von Schoen-Angerer, Director, MSF Campaign for Access to Essential=
=0D
Medicines=0D
***********************=0D
=0D
Dear Colleagues,=0D
=0D
M=C3=A9decins Sans Fronti=C3=A8res would like to invite those attending the=
 37th=0D
Union World Conference on Lung Health to participate in a seminar from=0D
4.30-6.30pm on Friday 3rd November, in Room 343 of the Palais des Congr=C3=
=A8s,=0D
to discuss:=0D
=0D
XDR-TB: can the R&D pipelines respond to the challenge?=0D
=0D
I. Presentations=0D
=0D
Realities from the field=0D
Francis Varaine, M=C3=A9decins Sans Fronti=C3=A8res=0D
=0D
What can we expect from the tuberculosis R&D pipelines for drugs?=0D
Martina Casenghi, MSF Campaign for Access to Essential Medicines=0D
=0D
=E2=80=A6for diagnostics?=0D
Martine Usdin, MSF Campaign for Access to Essential Medicines=0D
=0D
=0D
II. Panel discussions: challenges in accelerating the development of new=0D
tools=0D
Moderator: Mark Harrington, Treatment Action Group=0D
=0D
Panellists=0D
Bernard Fourie, Medicine in Need, South Africa/Harvard=0D
Mel Spiegelman, Global Alliance for TB Drug Development=0D
WHO representative (to be confirmed)=0D
Maryline Bonnet, Epicentre=0D
Ruth McNerney, London School of Hygiene and Tropical Medicine=0D
Mark Perkins, Foundation for Innovative New Diagnostics=0D
=0D
For more information, contact: James Arkinstall or Sheila Shettle=0D
James.arkinstall@msf.org=0D
Sheila.shettle@msf.org